The Pharmacovigilance Risk Assessment Committee (PRAC) has initiated a formal review of Deanxit — the fixed-dose combination of flupentixol/melitracen — after regulators received reports of serious neurological and psychiatric adverse events. Reports described movement disorders such as tremor, stiffness, restlessness and involuntary movements. Investigators also noted cases involving memory and thinking problems. Some patients continued to experience symptoms after stopping the medicine.
The EMA published a start-of-referral communication for flupentixol/melitracen-containing medicinal products. The source article did not provide specific details on patient demographics, dosage, or the frequency of reported events. PRAC’s review will follow the referral procedure to assess the safety concerns and determine whether regulatory action is needed.
Healthcare professionals should consult the start-of-referral communication for updates. The committee’s announcement makes clear that further data and formal assessment steps will follow; the EMA page referenced contains the procedural link for stakeholders seeking the primary documents.
PRAC opened a separate safety-signal review after detecting increased reporting of hypersensitivity reactions associated with specific batches of human normal immunoglobulin medicines. These immunoglobulin products are used to prevent infections in people with antibody deficiencies and to treat disorders where the immune system attacks the body. Hypersensitivity reactions are a known risk for these products, and their product information already warns that serious allergic reactions can occur, even in patients who previously tolerated therapy.
Reported reactions cover a spectrum: mild cutaneous events such as rash and itching; more severe manifestations including anaphylaxis and angioedema. The committee’s review was prompted by clustering of such events tied to particular batches, which in several EU Member States led to precautionary batch recalls for products including Flebogamma DIF, Yimmugo and Gamunex. Those batches were withdrawn from the market as a safety measure.
PRAC investigators reported that the cause of the clusters has not been established to date. The source did not supply analytical findings, laboratory data, manufacturing root-cause analyses, or a timeline that would explain batch-level signals. It is also not yet known whether other human normal immunoglobulin products are affected.
To address these uncertainties, PRAC will evaluate all human normal immunoglobulin medicines regardless of administration route — intravenous, subcutaneous or intramuscular. The committee will request all relevant data from marketing authorisation holders and assess that information alongside available evidence to investigate potential causes and to decide whether additional risk minimisation measures are required.
PRAC reminded clinicians to follow existing warnings and precautions in product information, including monitoring patients during and after administration. Patients were urged to seek immediate medical attention if they experience signs of hypersensitivity such as rash, dizziness, palpitations, wheeze or breathing difficulty, even if they previously tolerated treatment.
The EMA said it will provide further communication on the outcome of PRAC’s review once conclusions are reached.
The PRAC meeting agenda for 26–29 October 2026 was published as a draft (Reference Number: EMA/PRAC/227255/2026). The agenda lists the items the committee discussed during the meeting; the source linked to the full PDF agenda but did not summarise individual session deliberations beyond the topics reported in this highlights page.
Readers interested in procedural context and the scope of the meeting should consult the published agenda for the complete list of items and documents referenced by the committee.
The EMA provided a text summary of PRAC monthly figures: four safety signals were noted (one started, three ongoing or concluded), 67 PSUR single assessments were recorded with recommendations split between centrally and nationally authorised medicines, 42 RMPs for centrally authorised medicines were reviewed, and 18 post-authorisation safety studies (PASSs) were considered in terms of protocols and study results. The summary also noted one referral was discussed and started during this period.
The source did not include numerical case counts tied to the Deanxit or immunoglobulin items, nor did it offer statistical analyses or denominators. PRAC’s statistics page and the agenda provide the administrative snapshot but not case-level granularity in this meeting highlight.
The highlights page referenced ongoing referral procedures, including the flupentixol/melitracen-containing products referral and a separate referral concerning parenteral iron-containing medicinal products. The source did not expand on the parenteral iron referral within this particular article; readers must consult the linked referral pages for full procedural histories and documents.
The EMA included concise definitions relevant to pharmacovigilance work: safety signal assessments, periodic safety update reports (PSURs), risk management plans (RMPs) and post-authorisation safety studies (PASSs). These definitions describe the function and regulatory role of each element in PRAC’s evaluation process and were reproduced on the EMA page to orient non-specialist readers.
The EMA highlighted links to the PRAC event page, committee pages, and a related EMA document listing abbreviations used in committee publications. The source did not attach independent analyses or external studies; it focused on committee actions, published procedural documents and safety communications already posted on EMA’s website.
Limitations and next steps documented by PRAC
The committee stated that investigations into the human normal immunoglobulin clusters are ongoing and that the cause remains undetermined. PRAC will request comprehensive data from marketing authorisation holders to assess causality and to evaluate whether further measures are needed. For the flupentixol/melitracen review, PRAC has launched the referral process and will progress with the assessment according to established regulatory procedures. The EMA committed to communicating outcomes once PRAC completes its assessments.